## Andreja Figurek

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8983959/publications.pdf

Version: 2024-02-01

		1478505	1372567	
13	99	6	10	
papers	citations	h-index	g-index	
13	13	13	138	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Sclerostin: a new biomarker of CKD–MBD. International Urology and Nephrology, 2020, 52, 107-113.	1.4	26
2	Albuminuria as a risk factor for mild cognitive impairment and dementiaâ€"what is the evidence?. Nephrology Dialysis Transplantation, 2021, 37, ii55-ii62.	0.7	14
3	Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease–mineral and bone disorder?. International Urology and Nephrology, 2018, 50, 1863-1870.	1.4	11
4	Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges. Nephrology Dialysis Transplantation, 2021, 37, ii14-ii23.	0.7	11
5	Quantitative intravital Ca <sup>2+</sup> imaging maps single cell behavior to kidney tubular structure. American Journal of Physiology - Renal Physiology, 2020, 319, F245-F255.	2.7	7
6	Should We Consider the Cardiovascular System While Evaluating CKD-MBD?. Toxins, 2020, 12, 140.	3.4	7
7	FGF23 Level and Intimaâ€Media Thickness Are Elevated From Early Stages of Chronic Kidney Disease. Therapeutic Apheresis and Dialysis, 2018, 22, 40-48.	0.9	6
8	Brain dysfunction in tubular and tubulointerstitial kidney diseases. Nephrology Dialysis Transplantation, 2021, 37, ii46-ii55.	0.7	6
9	Phosphate in the Context of Cognitive Impairment and Other Neurological Disorders Occurrence in Chronic Kidney Disease. International Journal of Molecular Sciences, 2022, 23, 7362.	4.1	6
10	The Complexity of FGF23 Effects on Cardiomyocytes in Normal and Uremic Milieu. Cells, 2021, 10, 1266.	4.1	5
11	Reply to: "Risk Factors for Carotid Artery Disease and Chronic Kidney Disease: Same or Unique?― Carotid Artery Disease and Chronic Kidney Disease—Which Came the First: The Chicken or the Egg?. Therapeutic Apheresis and Dialysis, 2018, 22, 552-553.	0.9	0
12	What is the place of sclerostin in chronic kidney disease, atherosclerosis, and ageing?. International Urology and Nephrology, 2019, 51, 897-898.	1.4	0
13	Could Serum Sclerostin Help in Early Assessment and Treatment of Chronic Kidney Disease – Mineral and Bone Disorder?. Prilozi - Makedonska Akademija Na Naukite I Umetnostite Oddelenie Za Medicinski Nauki, 2019, 40, 133-134.	0.5	0